To the Editor:

Varied dosing regimens of rituximab (RTX) have been successfully used in the management of primary membranous nephropathy (PMN).[@bib1], [@bib2] An ideal RTX dose and the long-term adverse effect of a larger cumulative dose are not clear. CD19 levels are used to gauge the drug effect.[@bib1] Economic viability is a major part of any new therapeutic regimen. Low-dose RTX (100 mg) has been successfully used in ABO incompatible renal transplant.[@bib3] In the present study, we report a similar approach of CD19 depletion using 100 mg of RTX in the management of M-type phospholipase A2 receptor antibody (aPLA~2~R)-associated PMN refractory, dependent on or intolerant to conventional immunosuppressive regimens recommended by Kidney Disease: Improving Global Outcomes.[@bib4]

All the study subjects had aPLA~2~R-related PMN. The mean duration of nephrotic syndrome before RTX therapy was 33.67 ± 19.76 (median 13, range 10--62) months. Before receiving RTX, all the patients had an immunosuppression-free washout period of minimum 3 months. The mean proteinuria, serum albumin, and creatinine were 12.06 ± 10.78 (median 7.59, range 2.30--31.00) g/d, 2.09 ± 0.95 (median 1.64, range 1.30--3.50) g/dl, and 0.81 ± 0.21 (median 0.80, range 0.60--1.10) mg/dl, respectively. Five (83.3%) study subjects had nephrotic range proteinuria (\>4 g/d) and 1 (16.7%) patient had subnephrotic proteinuria (2.3 g/d) and was treated as he had anasarca with severe hypoalbuminemia (1.3 g/dl) and hypercholesteremia. All the study subjects (4 resistant to cyclophosphamide and steroids, 1 intolerant to tacrolimus treatment, and 1 with relapsing disease) were treated with 100 mg of rituximab (CD19 monitored on day 2 and at every 4- to 6-week interval). In subjects with no response at 6 months, further infusion and monitoring was stopped (extended follow-up continued). All the subjects achieved CD19 depletion (\<1%) with a single dose of 100 mg of RTX. All the patients received maximal tolerable doses of angiotensin receptor blockers (systolic blood pressure achieved was \<130 mm Hg in all the subjects) and atorvastatin; doses of angiotensin receptor blockers were stable during the entire study period. During RTX therapy, the patients received no other immunosuppressive therapy. At the end of 6 months, 3 (50%) achieved remission in proteinuria with normalization of serum albumin, and had maintained it until the last follow-up ([Table 1](#tbl1){ref-type="table"}). All the subjects in clinical remission also had serological remission and nonresponders had persisting aPLA~2~R ([Table 1](#tbl1){ref-type="table"}). The mean time for CD19 reconstitution was 2.17 ± 1.17 (median 2, range 1--4) months. A total of 16 additional doses of RTX were required (mean 2.67 ± 0.82, median 2.5, and range 2--4).Table 1Clinical and biochemical parameters of all the 6 subjectsS No.Primary ISTIndication*Baseline*Second *month completion*Fourth *month completion*Sixth *month completion*F/U\
(mo)*Last follow-upaPLA*~*2*~*R (RU/ml)RTX*UP\
(g/d)Sr Alb\
(g/dl)UP\
(g/d)Sr Alb\
(g/dl)UP\
(g/d)Sr Alb\
(g/dl)UP\
(g/d)Sr Alb\
(g/dl)UP\
(g/d)Sr Alb\
(g/dl)Pre-RTXPost-RTXAdditional dosesTime\
(mo)1cCTX/GCRelapse8.983.103.883.103.603.201.033.60140.7013.7073.114.5280203, 082cCTX/GCResistant6.201.401.205.501.255.203.002.10123.203.10121.5993.990301, 04, 053TACIntolerant2.301.302.903.132.863.421.924.32150.294.3228.872.000404, 09, 12, 154cCTX/GCResistant5.503.502.903.903.103.203.204.40131.134.34111.872.000202, 065cCTX/GCResistant31.001.6816.2201.593.801.9819.601.83108.803.5027.1379.760201, 046cCTX/GC[a](#tbl1fna){ref-type="table-fn"}Resistant18.411.6015.031.309.582.638.002.00143.133.3059.8956.790302, 05, 06[^1][^2][^3]

Low-dose RTX has been successfully used in ABO incompatible renal transplant. Nakao *et al.*[@bib3] reported successful use of 100 mg of RTX in 9 ABO incompatible renal transplant, with no difference in survival rates between low versus standard dose. Low dose of RTX has also been successfully evaluated in refractory rheumatoid arthritis.[@bib5] Shenoy *et al.*[@bib5] evaluated the therapeutic response of 100 mg of RTX in 14 patients with active rheumatoid arthritis; 58% and 42% of the patients achieved good and moderate response at 24 weeks, respectively. Seventy-nine percent of the patients achieved CD19 depletion (\<0.01%) with single dose of RTX (100 mg). The CD19 depletion in the present study is better than that reported by Shenoy *et al.*; this may partly be explained by the difference in the definition of CD19 depletion (\<1% and \<5 cells in the present study vs. \<0.01% in the study by Shenoy *et al.*).[@bib5]

Ruggenenti *et al.*[@bib1] studied RTX use in 100 subjects with PMN and reported a response rate of 56% (18 of 32 cases), when used as a second line agent. In the present study, the response rate of 50% was similar to that reported by Ruggenenti *et al.*[@bib1] Ruggenenti *et al.* used a single dose of 375 mg/m^2^ in all the patients compared with 100 mg with CD19 monitoring in the present study. Treatment protocol utilizing RTX in PMN widely varies among various centers; some prefer to use "extended protocol" of weekly (375 mg/m^2^) RTX for 4 weeks,[@bib6] whereas others choose to use CD19 targeted RTX infusion. Interestingly, most of the studies have demonstrated successful depletion of CD19 with a single dose, questioning the benefit of additional dosing, and many centers have evolved from "extended protocol" to "CD19 targeted dosing."[@bib1], [@bib6] Assuming that CD19 depletion primarily translates to clinical response, any dose that achieves it must be acceptable. aPLA~2~R has very good association with clinical activity;[@bib7] in the present report, all the responders had reduction in aPLA~2~R to \<20 RU/ml, whereas none of the nonresponders achieved similar titer. Our results support the incorporation of aPLA~2~R monitoring in the management of difficult to treat PMN.

To conclude, in cost-restrained setting, low-dose RTX targeting CD19 depletion can be used in the management of PMN refractory to standard immunosuppressive therapies with the acceptable side effect profile.
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[^1]: Mean time to CD19 repletion was 2.17 ± 1.17 (range 1--4) mo and all the subjects received further therapy (median doses 2.5, range 2--4).

[^2]: aPLA~2~R, m-type phospholipase A2 receptor antibody; cCTX/GC, cyclical cyclophosphamide and steroids; F/U, follow-up; IST, immunosuppressive therapy; RTX, rituximab; Sr Alb, serum albumin; TAC, tacrolimus; UP, urine protein.

[^3]: Patient developed upper respiratory tract infection, which was successfully managed with oral antibiotics.
